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neurons from Alzheimer’s disease patients are
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An early substantial loss of basal forebrain cholinergic neurons (BFCNs) is a constant feature of Alzheimer’s disease
(AD) and is associated with deficits in spatial learning and memory. Induced pluripotent stem cells (iPSCs) derived
from patients with AD as well as from normal controls could be efficiently differentiated into neurons with
characteristics of BFCNs. We used BFCNs derived from iPSCs to model sporadic AD with a focus on patients with
ApoE3/E4 genotypes (AD-E3/E4). BFCNs derived from AD-E3/E4 patients showed typical AD biochemical features
evidenced by increased Aβ42/Aβ40 ratios. AD-E3/E4 neurons also exhibited altered responses to treatment with
γ-secretase inhibitors compared to control BFCNs or neurons derived from patients with familial AD. BFCNs from
patients with AD-E3/E4 also exhibited increased vulnerability to glutamate-mediated cell death which correlated
with increased intracellular free calcium upon glutamate exposure. The ability to generate BFCNs with an AD
phenotype is a significant step both for understanding disease mechanisms and for facilitating screening for agents
that promote synaptic integrity and neuronal survival.
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Alzheimer’s disease (AD) is a progressive debilitating neu-
rodegenerative disorder that typically occurs in the elderly.
The majority of AD cases are sporadic without any known
genetic mutations. However polymorphism in the Apolipo-
protein E (ApoE) gene is a strong risk factor for AD. Com-
pared to individuals with an ApoE3/E3 genotype, the
presence of one copy of the E4 allele increases AD risk by 2
to 3 fold, and two copies of E4 increases risk up to 12 fold
[1,2].
The etiology of AD is poorly understood, but there are
consistent pathologic features of diseased brains including
senile plaques composed of β-amyloid [3,4], and neurofib-
rillary tangles formed by hyperphosphorylated tau [5].
β-amyloid plaques are comprised of aggregated, extracellu-
larly deposited Aβ peptides. Aβ peptides are typically 39–* Correspondence: LishuDuan2011@u.northwestern.edu
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reproduction in any medium, provided the or42 amino-acids long and are generated from amyloid pre-
cursor protein (APP) by sequential β- and γ-secretase cleav-
ages. Aβ40 is normally the major form of secreted Aβ
peptide recovered from cerebrospinal fluid, while Aβ42 rep-
resents less than 10% [6]. However, in AD, the more
amyloidogenic Aβ42 is significantly elevated and is hypoth-
esized to be the initial and predominant species found in
plaques [7]. The progressive cognitive decline of AD is a
consequence of loss of synapses and eventually neurons in
basal forebrain, cortex and hippocampus [8,9]. Basal fore-
brain cholinergic neurons (BFCNs) are the predominant
source of cortical cholinergic input and play a central role
in spatial learning and memory. AD-related tauopathies
arise earliest in cholinergic neurons of the basal forebrain
and loss of these neurons parallels cognitive decline [10,11].
For these reasons this population of neurons is an ideal tar-
get for the study of the cellular pathophysiology of AD.
Study of Alzheimer’s disease has been limited in the
past by the lack of availability of live neurons derived
from AD patients. However induced pluripotent stem
cells (iPSCs) can be derived from human skin fibroblaststd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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entiated into neurons [12,13]. Mixed neuronal cultures
derived in such a way from AD patients displayed some
biochemical features of the disease including increased
Aβ42/40 ratios, elevated levels of Aβ42 or Aβ40, and in-
creased phosphorylation of tau [14-16]. However the ab-
normalities in these studies were largely demonstrated
for familial AD caused by genetic mutations in presenilin
or APP, and disease manifestations were highly variable
in the limited sporadic AD lines that were examined.
We previously developed a protocol to generate a high
percentage of BFCNs from human embryonic stem cells
(hESCs) [17]. In this report we find that the same tech-
niques can be used to generate BFCNs with high effi-
ciency from iPSCs. We focused on sporadic AD with an
ApoE3/E4 genotype and found that BFCNs derived from
such patients display biochemical abnormalities associ-
ated with the disease and are more susceptible to both
glutamate- and calcium- mediated cell death.
Results
Generation of iPSCs from human control and Alzheimer’s
disease fibroblasts
Age matched human fibroblasts were purchased from
Coriell institute from either healthy controls or Alzhei-
mer’s disease patients with ApoE3/E4 genotypes. iPSCs
were generated with a polycistronic retroviral vector en-
coding Klf4, Oct4, Sox2 and c-Myc (Additional file 1:
Figure S1). Individual colonies were picked and ex-
panded as separate lines. We established control iPSCs
lines from the following subjects: control1, a 43-year-old
female; control2, a 71-year old female; control3, a
61-year old male; an iPSCs line from WiCell (iPS-DF6-
9-9T) was used as a fourth control. Sporadic Alzheimer’s
disease iPSC lines with ApoE3/E4 genotypes in-
cluded: AG05810, a 79-year old female with late AD on-
set; AG04402, a 47-year old male with early AD onset;
and AG11414, a 39-year old male with early AD onset.
We also included two familial AD lines in some of our
studies as comparators: AG06848, a 56-year-old femaleTable 1 List of iPSCs
Name Gender Age taken Fig
Control1 Male 61 1,2
Control2 Female 43 4,5
Control3 Female 71 4,5
Control4 Male N/A 4
AG04402 Male 47 4,5
AG11414 Male 39 3,4
AG05810 Female 79 4,5
AG07872 Male 53 4
AG066848 Female 56 4with a presenilin1 point mutation and AG07872, a 53-
year-old male AD patient with genetic mutations. A
complete list of iPSCs lines we used is provided in
Table 1.
All control and AD iPSCs lines showed typical hu-
man embryonic stem cell (hESC) morphology and
maintained normal karyotypes during culturing (data
not shown). Undifferentiated iPSCs all immunostained
for the pluripotent stem cell markers Oct4, Sox2,
SSEA4, andTra1-60 (Additional file 2: Figure S2A).
When differentiated in vitro using embryoid body for-
mation, both control and AD iPSCs gave rise to cell
types of all three germ layers, as demonstrated by
marker staining, Collagen type IV (mesoderm), Gata4
(endoderm) and Map2 (ectoderm) (Additional file 2:
Figure S2B). Some lines were also tested for their
ability to form teretaomas, and the tested lines were
able to generate teratomas with features characteristic
of mesoderm, endoderm and ectoderm (Additional
file 2: Figure S2C), further confirming their pluripo-
tent stem cell identity.
Electrophysiologically active BFCNs generation from
control and AD iPSCs
Our laboratory previously reported generation from
hESCs of highly enriched cultures of cells with the char-
acteristics of BFCNs [17]. Although iPSCs are similar to
hESCs, they are not identical and can have differences
such as differential promoter methylation states and
gene expression patterns [18]. We therefore asked if the
protocol used to generate BFCNs from hESCs could be
applied to iPSCs. We treated iPSCs grown on feeder free
matrigel matrix with retinoic acid for 7 days and dissoci-
ated cells for neurosphere formation. Robust neuro-
sphere formation was seen with both control and AD
iPSCs. Sonic hedgehog (SHH) and FGF8 signaling are
involved in patterning BFCNs precursors in the medial
ganglion eminence (MGE) during the development of
ventral forebrain [19,20] and are required for BFCNs
generation from hESCs [17]. We therefore asked if iPSCsures presented Vendor Specification
,3,4,5,S4,S5,S6 Coreill Healthy control
,6,S4 ATCC Healthy control
,S4 Coreill Healthy control
WiCell Healthy control
,6,S2,S4,S5 Coriell AD, Early APOE3/E4
,5,S2,S4,S5,S6 Coriell AD, Early APOE3/E4
,6,S4 Coriell AD, Late APOE3/E4
Coriell AD, Familial
Coriell AD, PS1 (A246E)
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entiated accordingly into a ventral forebrain pre-
cursor phenotype. Treatment of control iPSCs-derivedFigure 1 Differentiation of iPSCs into ventral forebrain neural progen
neural progenitors result in translocation of downstream effector Gli1 into
of the SHH downstream genes Ptch1 and Shh and the FGF8 downstream g
neurospheres. Data are normalized to non-treated controls (n = 4, mean ± S
comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, n indicates number of repli
treated neurospheres for forebrain marker (B) Forse1, ventral markers (C) N
Nuclei are stained with DAPI in blue. (F) Immunocytochemistry of SHH and
marker FoxG1 which co-localizes in the nucleus with DAPI.neurospheres with 200 ng/ml SHH and 100 ng/ml FGF8
for 72 hours resulted in translocation of the SHH down-
stream effector Gli1 into the nucleus (Figure 1A).itors. (A) 72 hours of SHH treatment of iPSCs (Control 1 line)-derived
the nucleus, Scale bar = 42 μm. Quantitative PCR shows up-regulation
enes Etv5 and Spry2 after 72 hours of SHH and FGF8 treatment of
EM, two-way ANOVA, p = 0.0003, F(1,32) = 17.73; Bonferroni multiple
cative experiments). Immunocytochemistry analysis of SHH and FGF8
kx2.1 and (E) Mash1 and dorsal marker (D) Pax6. Scale bars = 85 μm.
FGF8 treated neurospheres shows expression of the telencephalic
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of the SHH downstream molecules Ptch1 and Shh [21]
and the FGF8 downstream molecules Etv5 and Spry2
[22,23] (Figure 1A). Thus iPSCs respond to SHH and
FGF8 treatment by activating their appropriate down-
stream targets. To examine if the SHH/FGF8 treated
iPSCs neurospheres were relevant progenitors for
BFCNs, we immunostained the neurospheres for known
MGE markers. SHH/FGF8 treated control iPSCs
neurospheres expressed the forebrain marker Forse1
(Figure 1B) and the ventral markers Nkx2.1 and Mash1
(Figure 1C, E), but were negative for the dorsal marker
Pax6 (Figure 1D). The cells also expressed the telence-
phalic marker FoxG1 (Figure 1F). Taken together, these
results suggest that patterning iPSCs-derived neuro-
spheres with SHH and FGF8 directed the cells towards aFigure 2 Generation of basal forebrain cholinergic neurons from iPSC
progenitors (Control 1 line shown) are Map2 positive neurons. (B) ChAT po
FGF8 treated neural progenitors with Lhx8/Gbx1 transcription factors. (C) Q
neurons in SHH/FGF8 treated and Lhx8/Gbx1 nucleofected culture compar
t-test, ****p < 0.0001, n indicates number of replicative experiments). Furthe
staining with (D) VAChT (E) co-expression of ChAT with Nkx2.1 (F) expressi
HB9. Scale bars = 16 μm for panel D and 85 μm for other panels. Nucleus iventral forebrain progenitor phenotype, making them
relevant progenitors for BFCNs.
Two transcription factors, Lhx8 and Gbx1, are crucial for
BFCNs specification from committed progenitors in mice
[24,25], and we have previously demonstrated that Lhx8
and Gbx1 are both necessary and sufficient for BFCNs in-
duction from hESC-derived neurospheres [17]. We there-
fore transiently expressed Lhx8/Gbx1-IRES-EGFP plasmid
in dissociated SHH/FGF8 treated control iPSCs-derived
neurospheres via nucleofection. 72 hours later, we used
fluorescence-activated cell sorting (FACS) for EGFP to en-
rich for BFCNs progenitors which co-expressed Lhx8 and
Gbx1 and then plated the cells for differentiation in neuro-
basal medium with nerve growth factor (NGF) (Additional
file 3: Figure S3). Two weeks later, we examined the final
subtype of neurons by immunostaining. More than 95% ofs. (A) Over 90% of cells derived from SHH/FGF8 treated neural
sitive cholinergic neurons are generated after nucleofection of SHH/
uantification of ChAT positive neurons among total Map2 positive
ed to non-treated, non-nucleofected control group (n = 3, Student’s
r confirmation of basal forebrain cholingeric identity was done by
on of BFCN specific marker p75-NTR but not spinal cholinergic marker
s stained with DAPI in blue.
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mately 66 ± 3% of these neurons expressed the cho-
linergic neuron marker choline acetyltransferase (ChAT)
(Figure 2B, C) as well as another cholinergic marker, the
vesicular acetylcholine transporter (VAChT) (Figure 2D).
To further confirm the phenotype of these cells, we exam-
ined expression of two markers characteristic of BFCNs,
the low affinity neurotrophin receptor p75 shown be to
expressed by over 95% of BFCNs [26] and Nkx2.1 reported
to persist in postmitotic BFCNs [27]. Immunostaining re-
vealed co-localization of ChAT with Nkx2.1 (Figure 2E);
and expression of p75, by contrast the cells did not express
HB9, a cholinergic motor neuron marker (Figure 2F). There
were no significant differences in the efficiency of differenti-
ation of AD and control BFCNs either into ventral fore-
brain neural precursors or basal forebrain cholinergic
neurons (Additional file 4: Figure S4). Thus we were able to
differentiate both control and AD iPSCs into a BFCNs
phenotype by nucleofection of specific transcription factors.
Voltage clamp recordings of 2-week old BFCNs
cultures were performed to determine if the cells
were electrophysiologically active in culture. Control
neuron cultures showed voltage-activated currentsFigure 3 Control and AD iPSCs-derived BFCNs express functional volt
traces evoked by step depolarization in the absence (A, C) or presence of
BFCNs, note the elimination of the fast-inactivating inward current in the p
Fura-2 showed calcium transients evoked by depolarization with 56 mM KC
was added as a control for metabolically active neurons. (F) 2-week old co
influx was monitored by calcium imaging. Peak amplitude from 25 cells we
indicate SEM of each data point, n = 3, n indicates number of replicative ex(Figure 3A). The inward current was blocked by
tetrodotoxin (TTX) (Figure 3B), a selective voltage-
gated sodium channel blocker, demonstrating the
presence of functional sodium channels. AD iPSCs-
derived neurons similarly expressed tetrodotoxin-
sensitive voltage-activated currents as illustrated by
voltage clamp recordings in line AG11414 (Figure
3C, D). Depolarization of BFCNs with high KCl
(56mM) elicited significant calcium influx in control
neurons shown by calcium imaging with Fura-2 cal-
cium dye (Figure 3E), indicating expression of
voltage-gated calcium channels. AD neurons also
expressed functional voltage-gated calcium channels
and the amount of calcium influx through such chan-
nels upon KCl stimulation was not significantly differ-
ent from control in the lines tested (Figure 3F, n = 3).
The presence of voltage-gated calcium channels in
both control and AD BFCNs were further confirmed
by western blot using an L-type calcium channel anti-
body (Additional file 5: Figure S5). Taken together,
these observations indicate that we were able to use
our previously established protocol to differentiate
both control and AD iPSCs into highly enrichedage-gated sodium and calcium channels. Representative current
TTX (B, D) from 2-week old control1 and ApoE3/E4 AD line AG11414
resence of TTX. Scale bar = 1 nA, 10 ms. (E) Calcium imaging with
l (black arrow indicates time of addition) of 2-week old BFCNs. ATP
ntrol and AD BFCNs were briefly exposed to 56 mM KCl and calcium
re averaged and normalized to baseline for each group, dashed lines
periments.
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BFCNs markers and that were electrophysiologically
active.
AD-E3/E4 BFCNs have increased Aβ42/40 ratios and
altered responses to γ-secretase inhibitors
To test if our iPSCs-derived BFCNs from AD-E3/E4 pa-
tients display any disease related phenotypes, we exam-
ined Aβ secretion by the cells. In addition to the normal
controls we also included two familial AD cases as po-
tential positive controls. 300,000 neurons derived from
each line were cultured on 12-well plates in 1 ml
medium for 3 days and the medium was assayed simul-
taneously for Aβ42 and Aβ40 by sandwich ELISA. Cellu-
lar protein was extracted and measured by BCA protein
assay to control for input cell number. ELISA results
were read within the linear range of the standard curves
and Aβ concentrations were calculated and normalized
to cellular protein level. There were no significant differ-
ences in the amount of secreted Aβ40 among the lines,
ranging between 200 and 300 picograms per milligram
of cellular protein (data not shown). However Aβ42 se-
cretion was significantly increased in several AD linesFigure 4 AD-E3/E4 BFCNs have elevated Aβ42/Aβ40 ratios and altere
300,000 neurons for 72 hours was assayed simultaneously for soluble Aβ40
to cellular protein. (A) Aβ42 levels were significantly elevated in familial AD
to the average of controls (n = 4, mean ± SEM, one-way ANOVA, p < 0.0001
****p < 0.0001). (B) The ratios of secreted Aβ42 to Aβ40 were compared to
p < 0.0001, F(5,36) = 34.70; Bonferroni multiple comparisons, ****p < 0.0001)
dosages of γ-secretase inhibitor compound E (C) or DAPT (D) treatment. (n
number of replicative experiments from the same line.(Figure 4A). As a result, Aβ42/ Aβ40 ratios were signifi-
cantly elevated in AD-E3/E4 lines AG04402 (~3 fold,
n = 4, p < 0.0001) and AG11414 (~4 fold, n = 4,
p < 0.0001) as well as in familial line AG07872 (~2.5 fold,
n = 4, p < 0.0001) compared to the average of controls
(Figure 4B). However, Aβ42/β40 ratios were not elevated
in familial line AG06848 or in AD-E3/E4 line AG05810.
We then examined the effects of treatment with the γ-
secretase inhibitor, compound E (IC50 = 300 pM). At a
concentration of 200 pM the γ-secretase inhibitor re-
duced Aβ40 production as expected in the familial and
control lines that were tested (Figure 4C). Surprisingly,
the treatment paradoxically increased Aβ40 secretion in
the AD-E3/E4 line AG11414 by 67 ± 24% (Figure 4C).
At a concentration of 400 pM the inhibitor further re-
duced production of Aβ40 in familial lines AG06848 (59
± 11% reduction), AG07872 (43 ± 4% reduction), and
control2 (60 ± 19% reduction), but it increased Aβ40
production from AG11414 (35 ± 20% increase). To de-
termine whether this paradoxical response occurred in
other sporadic AD lines and with other inhibitors, we
tested another γ-secretase inhibitor DAPT (IC50 = 20
nM) in more lines. A similar shift in γ-secretased responses to γ-secretase inhibitors. Medium conditioned by
and Aβ42 by sandwich ELISA. Levels of Aβ secretion were normalized
line AG07872 and ApoE3/E4 lines AG04402 and AG11414 compared
, F(5,36) = 24.16; Bonferroni multiple comparisons, **p < 0.01,
the average of controls (n = 4, mean ± SEM, one-way ANOVA,
. (C, D) Quantification of Aβ40 secretion in response to different
= 3, mean ± SEM, Student’s t-test, *p < 0.5, ***p < 0.001), n indicates
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observed. Aβ40 secretion was increased by 45 ± 6% and
15 ± 6% at 100 nM and 200 nM DAPT concentrations
respectively in AG04402. By contrast, the inhibitor re-
duced secretion as expected in the control line and in
AG05810. At higher concentrations, (400 nM and 800
nM) DAPT inhibited Aβ40 production from all lines in-
cluding AG04402 (Figure 4D). Although individual vari-
ances were observed, these findings indicate that BFCNs
derived from AD patients with an ApoE3/E4 genotype
demonstrate Aβ secretion abnormalities in vitro.
AD-E3/E4 BFCNs show increased sensitivity to neurotoxic
stimuli
BFCNs degenerate early in the course of AD. Since we have
a system that allows us to directly assess human BFCNs
survival, we compared AD-E3/E4 and control BFCNs for
susceptibility to cell death. The precise mechanisms of
neuronal death in AD are still unclear, but multiple pro-
posed mechanisms ultimately converge on disrupted cal-
cium signaling [28]. AD mutations have been reported to
deregulate calcium signaling and sensitize neurons to apop-
tosis [29]. To determine whether AD-E3/E4 BFCNS are
more susceptible to calcium-mediated cell death, 2-week
old BFCNs were treated with three different doses of the
calcium ionophore, ionomycin (250 nM, 1 μM or 15 μM)
or with buffer (DSMO) for 16 hours, and a live/dead assay
was performed to assess cell viability (Additional file 6:
Figure S6). Neither the control nor AD groups had signifi-
cant cell death after exposure to 250 nM ionomycin (data
not shown). 1 μM ionomycin treatment had little effect on
cell viability of control neurons, but it reduced cell viability
by about 50% in AD-E3/E4 line AG11414 (Two-way
ANOVA, n = 3, p < 0.01) (Figure 5A). High concentrationsFigure 5 AD-E3/E4 BFCNs are more sensitive to ionomycin or glutam
or 15 μM ionomycin for 16 hours, live/dead assay was performed and quan
ANOVA, p = 0.0001, F(2,18) = 20.53; Bonferroni multiple comparisons, *p < 0
replicative experiments from the same line). (B) 2-week old BFCNs were ex
incubated for another 24 hours. Cell viability was quantified by MTT assay.
mean ± SEM, two-way ANOVA, p < 0.0001, F(1, 36) = 38.43; Bonferroni multi
indicates number of replicative experiments from the same line).(15 μM) of ionomycin killed more than 70% of both control
and AD neurons. Thus BFCNs derived from the AD-E3/E4
AG11414 died in response to low, normally non-lethal
amounts of calcium influx.
Calcium ionophores make all membranes permeable to
calcium, including plasma membranes, mitochondria and
endoplasmic reticulum, which is unlikely to happen in vivo.
To determine if sporadic AD-E3/E4 BFCNs are also more
susceptible to more physiologically relevant neurotoxic
stimuli, we examined their susceptibility to excitotoxic
death in response to glutamate. 2-week old neuronal cul-
tures were treated with either saline or 50 μM L-glutamic
acid for 15 minutes, washed with PBS, and incubated with
culture medium for additional 24 hours. The MTT assay,
which takes advantage of color conversion of the MTT dye
by mitochondrial succinate dehydrogenase of living cells,
was used to quantify cell viability according to the manufac-
turer’s protocol. We included three controls and two iPSCs
lines from the same sporadic AD patient AG04402 to ad-
dress concerns about possible inter-line variance. The con-
trol BFCNs did not show a significant reduction in cell
viability upon 50 μM glutamate exposure. Late-onset AD-
E3/E4 line AG05810 had a 44% reduction is cell number.
Cell survival after glutamate exposure was also significantly
reduced in both lines independently derived from early on-
set AD-E3/E4 line AG04402; there was a 62% reduction in
cell numbers in the line labeled as 4402 and a 53% decrease
in line 4402–2 (Two-way ANOVA, n = 3, p < 0.0001 and p
< 0.01 respectively) (Figure 5B). Thus BFCNs derived from
AD-E3/E4 iPSCs displayed increased susceptibility to
glutamate-induced excitotoxic death. The data with two
different lines from the same AD-E3/E4 patient, combined
with the consistency of phenotypes in multiple control
lines, suggest that the observed difference is unlikely to beate treatment. (A) 2-week old BFCNs were treated with DMSO, 1 μM
tified, DMSO control is normalized to 1. (n = 3, mean ± SEM, two-way
.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n indicates number of
posed to saline or 50 μM glutamate for 15 minutes and cells were
Both sets of data are presented as percentages of living cells. (n = 3,
ple comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n
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reflects intrinsic genetic and disease stage associated
abnormalities.
AD-E3/E4 BFCNs show increased cytoplasmic calcium
levels upon glutamate exposure
Neuronal excitotoxicity is thought to be mediated by cal-
cium dependent processes [30]. To test if calcium signal-
ing differences were associated with the differential
susceptibility of control versus AD-E3/E4 BFCNs to glu-
tamate, we examined calcium dynamics using Fura-2
calcium imaging. 2-week old neurons were incubated
with 2 μM Fura-2 for 30 minutes, washed and incubated
for another 30 minutes before imaging. Magnesium was
excluded from all buffers to relieve the voltage-
dependent block of NMDA receptors. Baseline level sig-
nals were established for 10 minutes before 50 μM glu-
tamate was added briefly for 1 minute and the ratio of
340 nm to 380 nm was recorded. An enhanced calcium
signal was seen strongly in both the cell bodies and in
neuronal processes (Figure 6B and C). The calcium tran-
sient was quantified by subtracting the baseline from the
peak value and then dividing by the baseline value for
each individual neuron. 20–30 neurons from each ex-
periment were analyzed and the responses were aver-
aged. The control lines had approximately 70% increases
of free intracellular calcium when briefly exposed to glu-
tamate. By contrast, AG05810 neurons had an increase
of over 90%, and AG04402 had about 110% increase in
intracellular calcium levels (Figure 6A). The calcium
transient was significantly higher in AD-E3/E4 lines
AG05810 and AG04402 compared to the average of cal-
cium transient in controls (One-way ANOVA, n = 3,
p < 0.01 and p < 0.0001 respectively). We also measured
resting free calcium concentrations and found no
statistically significant differences among the lines
examined. Control neurons had free cytosolic calcium
concentrations ranging between 50-80 nM, whereas con-
centrations for AG05810 were between 90-120 nM, andFigure 6 AD-E3/E4 BFCNs have increased cytoplasmic calcium levels u
exposed to 50 μM glutamate and responses were recorded by calcium ima
and peak amplitude is measured for each individual cell and cytosolic free
(A) Averages of calcium transient of 20–30 cells per experiment were calcu
ANOVA, p = 0,0005, F(3, 12) = 19.55; Bonferroni multiple comparisons, **p <
the same line. Representative images of imaged cells at 340nm (B) and 38for AG04402 between 108-162 nM. These observations
suggest that the increased sensitivity of AD-E3/E4 neu-
rons to glutamate toxicity may reflect elevated cytoplas-
mic calcium levels upon stimulation.
Discussion
The ability to generate BFCNs with an AD phenotype is a
significant step both for understanding disease mechanisms
and for facilitating screening for agents that promote syn-
aptic integrity and neuronal survival. Generation of rela-
tively pure subpopulations of any type of neurons from
iPSCs is difficult, and differentiation of BFCNs required a
detailed protocol that was first established for the differenti-
ation of hESCs [17]. Some approaches for the differenti-
ation of hESCs and iPSCs are inefficient for generating
BFCNs [31], and we used an approach that included retin-
oic acid followed by specific factors to induce a forebrain
phenotype (SHH and FGF8) and nuclefection with two
transcription factors (Lhx8 and Gbx1) that specify the
BFCNs phenotype. Although retinoic acid (RA) may have
some caudalizing effects, its use for generating forebrain
precursors is well established [32,33]. SHH and FGF8 pre-
treated neural progenitors immunostained for the ventral
marker Nkx2.1 and forebrain specific marker Forse1 [34],
confirming the presence of a ventral forebrain progenitor
population. The cells also expressed the forebrain marker
FoxG1 which is initially detected in the cytoplasm [17]
followed by translocation to the nucleus (Figure 1) as the
cells begin to differentiate. Finally the cells expressed all of
the known markers of the BFCNs phenotype and were elec-
trically excitable. Although the protocol involved directed
differentiation of the iPSCs, it is likely that the very high
final purity of the cultures of BFCNs partially reflected se-
lection due to early AraC treatment to eliminate proliferat-
ing cells and later NGF treatment to promote survival of
BFCNs. These cultures should be useful not only for study-
ing disease mechanisms but also for drug screening. For ex-
ample, the glutamate excitotoxicity assay with MTT
reagent (Figure 5) provides a direct readout for neuronalpon glutamate stimulation. 2-week old neurons were briefly
ging and measured by ratio of signals at 340 nm/380 nm. Baseline
calcium levels were calculated as (peak amplitude-baseline)/baseline.
lated and compared to the average of controls (n = 4, mean ± SEM,
0.01, ****p < 0.001), n indicates number of replicative experiments from
0nm (C) are shown. Scale bar = 85 μm.
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mat would provide a method for high-throughput screen-
ing for drugs that promote BFCNs survival.
There have been at least three prior studies that utilized
iPSCs to study AD, but all examined heterogeneous mix-
tures of differentiated cells [14-16]. None of those studies
examined cells from AD-E3/E4 patients, but they did
examine cells from a few cases of sporadic AD and found
great inconsistency in the phenotypes in vitro. Israel et al.
reported increased Aβ40 secretion in one sporadic line
(ApoE3/E3) but not the other [15]. Kondo et al. found that
only one of the two sporadic cases (genotype not known)
had neuronal Aβ oligomer accumulation [16]. Some of the
variability in those studies may reflect the heterogeneous,
uncharacterized phenotypes of the differentiated cells that
were examined. However heterogeneity was also observed
in our study that focused on BFCNs. Although the findings
with control cultures were remarkably consistent and re-
producible across the four control lines used in our study,
there were differences among the AD-E3/E4 lines. The
AG11414 (ApoE3/E4) and AG04402 (ApoE3/E4) lines both
differed significantly from controls in terms elevation of
Aβ42/Aβ40 ratios, a paradoxical response to γ-secretase in-
hibitors, and increased sensitivity to glutamate induced tox-
icity. However the AG05810 (ApoE3/E4) line did not differ
significantly from the controls in these respects. The rea-
sons for these disparate findings are not yet clear, but there
are a number of possibilities. The ages of onset of disease
for AG11414 (35 y.o.) and AG04402 (47 y.o. and possibly
earlier) were substantially younger than for AG05810 (79
y.o.), so the difference might reflect differences between early
onset versus late onset disease. It is also possible that the
lines produce different amounts of ApoE4 protein. It is well
recognized that the ApoE4 allele accelerates the onset of
AD [35], and the late onset for AG05810 suggests less of an
effect of the ApoE4 allele. We attempted to find out if there
was differential ApoE4 protein expression compared to
ApoE3 protein level among these lines by western blot
using a commercially available ApoE4 specific antibody.
Unfortunately the antibody was not specific and recognized
ApoE3 protein as well. Inter-line variance could also ac-
count for some of the differences since we used retrovirus
to generate our iPSCs, and genome integration could lead
to clonal heterogeneity and potential functional diversity
[36]. However we tested this by examining two different in-
dependently derived lines from the same patient and found
no significant differences. Coupled with the findings by
other investigators, our observations suggest that it is likely
patient specific factors rather than differences in repro-
gramming among lines account for the observed
phenotypes.
As a major risk factor in sporadic AD, the ApoE4 allele
is associated with earlier onset and increased amyloid
plaques in AD [37-39]. Animal studies demonstrated anisoform-dependent (ApoE4 >ApoE3 >ApoE2) effect on
Aβ deposition [40,41]. ApoE4 also induced neuronal
Aβ42 accumulation in target replacement ApoE4 mice
[42]. Since astrocytes are the primary sources of secreted
ApoE in mice, and have been shown to bind and de-
grade amyloid deposits [43,44], the above effects are
thought to be primarily mediated by astroctyes. However
our cultures contained no detectable astrocytes, and al-
most all of the cells expressed neuronal traits. Thus the
effects of the ApoE4 allele in this study were not medi-
ated by astrocytes. Neurons also express ApoE [45,46],
and our data suggest that neuronal ApoE4 increases se-
cretion of Aβ42, the more fibrillar form that is more
likely to aggregate and act as the core for amyloid pla-
ques. In addition, we found an interesting shift of γ-
secretase inhibitor potency in ApoE3/E4 AD neurons.
Low concentrations of γ-secretase inhibitors significantly
increased Aβ secretion from ApoE3/E4 neurons, in con-
trast to the predicted reduction of Aβ seen in control
and familial AD lines. Such an Aβ rise at sub-threshold
concentrations of γ-secretase inhibitors has been de-
scribed in cell culture [47,48] and in vivo in human [49].
The underlying biochemical mechanism is not fully
understood, but it is thought to be a direct γ-secretase
effect [50,51]. Our finding that ApoE also plays a role in
this process is important since it suggests that thera-
peutic strategies that focus on secretase inhibition
should control for the presence of the ApoE4 allele.
Excitotoxicity is involved both in acute cell death after
CNS injuries and in the neuronal death that is part of
AD. Human ApoE4 carriers have poorer recovery after
head trauma or stroke [52,53] with severe neurodegener-
ation [54]. Some studies of transgenic mice that overex-
press ApoE3 or ApoE4 suggested a protective role of
ApoE3 against excitotoxicity compared to ApoE4 [55,56]
whereas other studies revealed no differences [57,58].
The controversy could be due to cellular source of
ApoE. Buttinit et al. showed that neuron-specific expres-
sion of ApoE4 promotes excitotoxic cortical neuron
death, whereas ApoE4 expressed by astrocytes was as
neuroprotective as ApoE3 [59,60]. Our findings that
AD-E3/E4 BFCNs are more susceptible to glutamate in-
duced excitotoxic death are consistent with the sugges-
tion that neuronal ApoE4 sensitizes neurons to
excitotoxicity.
The increased vulnerability of AD-E3/E4 BFCNs to
glutamate-mediated cell death correlated with increased
intracellular free calcium upon glutamate exposure. Re-
combinant truncated or full-length ApoE protein elicited
rapid elevation of intracellular calcium and induced ro-
dent cortical or hippocampal neuron death [61,62].
ApoE dose-dependently increased cytosolic free calcium
concentration in the order of E4 > E3 > E2 [63]. Disrup-
tion of calcium homeostasis mediated the neurotoxic
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duced calcium elevation could result from calcium influx
through NMDA receptors, metabotropic glutamate re-
ceptors, activation of voltage-sensitive calcium channels
(VSCCs), or mobilization of calcium from intracellular
calcium stores [65]. We found calcium influx through
VSCCs did not differ significantly between one control
and ApoE3/E4 line, consistent with previous findings of
a lack of contribution by VSCCs to calcium mediated
excitotoxicity [66,67]. Alternatively, abnormalities in the
cellular calcium buffering system could also result in
sustained intracellular calcium elevations.
Conclusions
In this study we modeled sporadic Alzheimer’s disease
with an ApoE3/E4 genotype using human iPSCs that we
established from age-matched control and AD-E3/E4 fi-
broblasts. We then differentiated the iPSCs into BFCNs
to enable us to study the disease process in an identified,
disease relevant population of human neurons. Using
these iPSC-derived BFCNs, we found that AD-E3/E4
neurons had increased Aβ42/Aβ40 ratios, a typical bio-
chemical feature of AD, similar to familial presenilin mu-
tation lines [14,16]. However we found that lower doses
of γ-secretase inhibitors surprisingly increased Aβ secre-
tion by AD-E3/E4 BFCNs whereas they reduced Aβ se-
cretion by control and familial AD neurons as expected.
AD-E3/E4 BFCNs also exhibited increased vulnerability
to normally non-lethal concentrations of calcium iono-
phore or L-glutamate. The excitotoxicity caused by glu-
tamate exposure correlated with increased cytosolic free
calcium in the AD-E3/E4 BFCNs upon stimulation. In
summary, iPSCs-derived BFCNs from patients with AD
and an ApoE3/E4 genotype display biochemical features
of the disease including an increased ratio of Aβ42/40
and increased susceptibility to cell death in response to
calcium influx or exposure to glutamate. The ability to
generate BFCNs with an AD phenotype is a significant
step both for understanding disease mechanisms and for
facilitating high throughput screening for agents that
promote BFCNs survival.
Methods
Reprogramming and cell culture
Human age-matched control and Alzheimer’s disease fi-
broblasts were purchased from the Coriell Cell Reposi-
tories and ATCC. Fibroblast cultures were maintained in
DMEM, 15% FBS (Fetal Bovine Serum). Fibroblasts were
infected with Oct4-Klf4-Sox2-cMyc retrovirus for two
rounds and split onto 75,000 cells/ml gamma-irradiated
feeder cells on day 6. Medium was switched to hESC
(human Embryonic Stem Cell) medium with DMEM/
F12, 20% KSR (Knock-out Serum Replacement), 0.1 mM
non-essential amino acids, 2 mM L-glutamine, 100 μMβ-mercaptoethanol, 10 ng/ml bFGF. Medium was chan-
ged every other day until colonies were picked up
around day 20 and then changed daily.
Teratoma assay and karyotyping
All animal procedures were performed in accordance
with the Public Service Policy on Human Care and Use
of Laboratory Animals and all procedures were approved
by the Northwestern University Institutional Animal
Care and Use Committee. iPSCs were harvested as ag-
gregates in hESC medium. Cells were injected subcuta-
neously through an 18-gauze needle into hind limbs of
NOD-SCID mice. After 6–8 weeks, mice were eutha-
nized and teratomas were excised, sectioned and ana-
lyzed by H&E staining. iPSCs were plated in T-25 cell
culture flasks and karyotyped by Children’s Hospital,
Oakland using standard G banding.
Differentiation of iPSCs
The protocol for generating BFCNs from iPSCs was
adapted from our previously described protocol for
hESCs [17]. Briefly, iPSCs were split onto matrigel plates
in feeder cell conditioned medium supplemented with
10 ng/ml bFGF and 10 μM RA. After 7 days, cells were
harvested in hESC medium without bFGF to allow neu-
rosphere formation. Individual neurospheres were then
picked into neurosphere medium (DMEM/F12, 0.1 mM
non-essential amino acids, 1× N2 supplement, 100 μM
β-mercaptoethanol, 8 μg/ml heparin, 20 ng/ml bFGF, 20
ng/ml EGF) for another 4 days. 100 ng/ml FGF8 and
200 ng/ml SHH were added for 72 hours at which point
neurospheres were dissociated and nucleofected with 4
μg Lhx8/Gbx1-IRES-GFP overexpression plasmid (for
control, GFP plasmid was used). 48–72 hours later, cells
were fac-sorted for GFP and plated in neurobasal
medium with 1× B-27 supplement, 2 mM glutamax, 2
mM glutamine, 20 ng/ml bFGF, 100 ng/ml NGF. Cyto-
sine arabinoside was added from day 5 to day 10 at a
concentration of 2.4 μM to eliminate proliferation of
contaminating non-neuronal cells.
Retrovirus production
The four human reprogramming factors were cloned into a
single retroviral vector linked by 2A sequences: pMXs-
Oct4-p2A-Klf4-t2A-Sox2-e2A-cMyc (pMXs-OKSM). 293T
cells were co-transfected with pMXs-OKSM, pCMV-VSVG
and pCMV-gag/pol. Supernatants from day 2 and 3 were
used to directly infect human fibroblasts in the presence of
5 ng/ml polybrene.
Quantitative PCR (Q-PCR)
RNA was extracted with an RNAequeous-Micro kit
(Ambion). A total of 500 ng RNA was used for cDNA
synthesis with the Thermoscript system (Invitrogen).
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(Applied Biosystems) and the PCR reaction was carried
out in a Realplex2 Mastercycler (Eppendorf ) using the
following cycling parameters: 95°C 15 s, 60°C 60 s for 40
cycles. Melting curves were generated to confirm the
presence of one single product.
ELISA and western blot
BFCNs were conditioned in neuron medium (see above)
for 72 hours. Human Aβ40 and Aβ42 ELISA (Invitro-
gen) were carried out simultaneously according to
the manufacturer’s instructions with the conditioned
medium. Cellular protein was harvested with M-PER
protein extraction reagent with 1:500 Halt protease in-
hibitor cocktail (Thermo Scientific). Protein concentra-
tion was determined by BCA assay. For western blot
analyses, protein samples were separated by SDS-PAGE
on 4-20% Tris-glycine gradient gels (Invitrogen), and
then transferred onto PDF (polyvinylidene difluoride)
membranes (Millipore). Membranes were blocked with
5% milk and then incubated with primary antibodies
overnight at 4°C. HRP (Horseradish peroxidase)-conju-
gated secondary antibodies and ECl substrate (Thermo
Scientific) were used for detection. Primary antibodies
included: Anti-Cav1.2 (1:200, Neuromab).
Neurotoxicity assays
Neurons were treated with DMSO, 250 nM, 1 μM or 15
μM ionomycin for 16 hours and Live/Dead Viability/Cyto-
toxicity assays (Invitrogen) were performed. Cells were in-
cubated in 2 μM calcein and 4 μM ethidium homodimer-1
for 30 minutes at room temperature and then immediately
mounted and imaged using Zeiss microscopy. For the glu-
tamate excitotoxicity assay, 50 μM glutamate or saline dis-
solved in 2 mM calcium buffer was added to 2-week
neuron cultures for 15 minutes and washed twice with PBS
before adding culture medium back in for another 24
hours. MTT assay from Promega was performed to deter-
mine cell viability according to manufactures’ instructions.
Immunocytochemistry
Cells were fixed in 4% PFA for 15 minutes followed by two
1xPBS washes. Cells were blocked by 10% bovine serum in
1xPBS at room temperature for 1 hour. Primary antibodies
were applied for overnight at 4°C in 1xPBS containing 1%
BSA and 0.25% Triton-X-100. Following three washes,
alexa fluor conjugated secondary antibodies (1:1000, invi-
trogen) together with DAPI (1:2000) were added for 1 hour.
After three more washes, coverslips were mounted with
Prolong Gold antifade reagent (Invitrogen) and imaged. Pri-
maries antibodies used were: Oct4 (1:1000, Santa Cruz),
Sox2 (1:1000, Millipore), Ssea4 (1:500, Chemicon), Tra1-60
(1:500, Chemicon), Collagen type IV (1:500, Abcam), Gata4
(1:1000, Santa Cruz), Map2 (1:1000, Abcam), Gli1 (1:500,Santa Cruz), Forse1 (1:300, DSHB), Nkx2.1 (1:500, Abcam),
Pax6 (1:1000, DHSB), Mash1 (1:1000, BD Pharmingen),
p75-NTR (1:1000, Abcam), VAChT (1:1000, SYSY), HB9
(1:1000, Abcam) and ChAT (1:600, Aves Labs).
Calcium imaging
2-week old neurons grown on PDL-coated glass cover-
slips were incubated with 2 μM calcium-sensitive dye
Fura-2 (Invitrogen) in calcium buffer for 30mins and
washed three times afterwards. Neurons were incubated
for an additional 30 mins before imaging. Coverslips
were mounted onto a chamber and placed on the stage
of a laser confocal microscope. A 20× objective was used
and the imaging was done at room temperature. Signals
were collected at 3 s intervals from wavelengths 340 nm
and 380 nm and the ratio of 340 nm/380 nm was re-
corded. Recordings were allowed to go for 10–15 mi-
nutes to establish baseline. 56 mM KCl or 50 μM
glutamate were added for 1 min to elicit calcium influx.
For measurement of cytosolic free cacium, 10 μM iono-
mycin was added to zero calcium buffer to deplete intra-
cellular calcium stores and to 20 mM calcium buffer to
get a maximal calcium level. Imaging buffers were ad-
justed to PH value of 7.2-7.4 and osmolality of 300–310.
Detailed description of buffers are listed below: Calcium
buffer: 125 mM NaCl, 3 mM KCl, 2 mM CaCl2, 25 mM
glucose, 10 mM Hepes; Zero calcium buffer: 125 mM
NaCl, 3 mM KCl, 25 mM glucose, 10 mM Hepes, 10
mM EDTA; High calcium buffer: 100 mM NaCl, 3 mM
KCl, 25 mM glucose, 10 mM Hepes, 20 mM CaCl2.
Electrophysiology
Cultured neurons were incubated for 15 min at 37°C in ox-
ygenated standard artificial CSF [ACSF] containing [in
mM]: 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 1.5
CaCl2, 1 MgSO4, and 10 glucose, saturated with 95% O2
and 5% CO2 at pH 7.4 and then transferred to the record-
ing chamber in oxygenated standard ACSF. Whole cell
patch clamp recordings were performed and observed with
the aid of microscope [BX-50WI; Olympus] and visualized
with a chilled charge-coupled device video camera [Dage-
MTI] with a 40× water-immersion differential interference
contrast objective. For whole cell voltage clamp recordings,
patch electrodes with a resistance of 5–7 M were pulled
from borosilicate capillaries [World Precision Instruments;
PG52165-glass]. Patch pipettes were filled with a solution
of [in mM] 150 KCl, 10 HEPES, 4 Mg2ATP, 0.5 NaGTP,
and 10 phosphocreatine. The pH was adjusted to 7.3 with
KOH. Whole-cell voltage clamped recordings were ob-
tained from neurons using an Axopatch 200B patch-clamp
amplifier [Molecular Devices] and the data were captured
with pClamp 9.0 software [Molecular Devices]. Voltage-
dependent Na currents was recorded under voltage clamp
conditions and blocked by bath application of Tetrodotoxin
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Data analysis. Data were filtered at 2 kHz and digitized at
10 kHz using a Digidata 1322A analog-to-digital board.
Analysis was performed using the pClamp 9.0 [Molecular
Devices].
Statistics
GraphPad software was used for statistical analyses. Stu-
dent’s t-test or ANOVA with the Bonferroni post test was
used to generate P values.
Additional files
Additional file 1: Figure S1. Polycistronic reprogramming vector map
and primer sequences. (A) Reprogramming factors in the order of Oct4, Klf4,
Sox2 and c-Myc were cloned into the MMLV-based retroviral backbone pMXs
linked by viral 2A sequences, (B) Oct4 and Klf4, Sox2 and c-Myc were cloned
using recombinant PCR and the resulting two fragments were ligated via XbaI
restriction site. Primers used are listed as shown.
Additional file 2: Figure S2. Induced pluripotent stem cell
characterization. (A) Undifferentiated iPSC colonies stained positive for
the pluripotent stem cell markers, Oct4, Sox2 (red), Ssea4 and Tra1-60
(green). Nuclear staining with DAPI is in blue. Scale bar = 85 μm. (control
2 line shown). (B) Following embryonic body differentiation, iPSCs gave
rise to cell types positive for Map2 (green, ectoderm), Gata4 (red,
endoderm) and Collagen type IV (green, mesoderm). Scale bar = 85 μm.
(AD-E3/E4 line 4402 shown). (C) iPSCs formed teratomas when injected
into mice. H&E staining revealed characteristic morphologies of all three
germ layers. Scale bar = 313 μm. (AD-E3/E4 line 11414 shown).
Additional file 3: Figure S3. Flow cytometry sorting for Lhx8/Gbx1/
EGFP plasmid nucleofected neural progenitor cells. Representative dot
plots of flow cytometry sorting for Lhx8/Gbx1/EGFP nucleofected neural
progenitor cells. (A) Dots (cells) within region R1 were live cells, this
portion of cells were further sorted for GFP. (B) Dots within region R3
were GFP positive cells, indicating cells had successfully taken up the
plasmid with Lhx8 and Gbx1 genes in it. GFP positive cells were sorted
and plated for further experiments.
Additional file 4: Figure S4. Basal forebrain cholinergic neuron
generation from AD iPSCs. (A) AD-E3/E4 line 11414 neurosphere sections after
SHH and FGF8 treatment stained positive for forebrain marker FoxG1 (green)
and ventral marker Nkx2.1 (red). (B) Representative confocal image of neurons
generated from AD-E3/E4 line 11414 stained with neuronal marker Map2 (red)
and basal forebrain cholinergic marker p75-NTR (green). Nuclear staining with
DAPI is in blue. Scale bar = 85 μm. (C) Quantification and comparison of
generation efficiency of ventral forebrain precursors, represented by the ratios
of Nkx2.1, Mash1 and FoxG1 positive cells to total DAPI positive cells
respectively. (D) Quantification and comparison of neuron generation
efficiency, represented by the ratios of Map2 positive cells to total DAPI
positive cells; and final basal forebrain cholinergic neuron purity counted as
the ratio of ChAT positive neurons to Map2 positive total neurons. There are
no statistically significant differences among control and AD lines in the ability
of generating ventral forebrain precursors or basal forebrain cholinergic
neurons (n = 3, mean ± SEM, two-way ANOVA, p = 0.9665 and p = 0.4701
respectively).
Additional file 5: Figure S5. Control and AD BFCNs express L-type
voltage gated calcium channel. Western blot analysis for expression of
voltage gated calcium channel by BFCNs in lines control1, 11414 and
4402-1. An anti-Cav1.2 monoclonal antibody was used to detect the α
subunit of voltage gated calcium channel at around 240 kD (upper
panel). GAPDH was also probed for loading control (lower panel).
Additional file 6: Figure S6. Live/dead assay for ionomycin induced
neuronal toxicity. 2-week old BFCNs from either AD (A) or control (B)
lines were treated with DMSO, 1 μM or 15 μM ionomycin for 16 hours,
live/dead assay was performed. Live cells were stained with green and
counted.Abbreviations
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